Trial reportJAMA oncology2022
Comparison of Prophylactic Intravenous Antibiotic Regimens After Endoprosthetic Reconstruction for Lower Extremity Bone Tumors: A Randomized Clinical Trial.
Trial report in JAMA oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01479283 (Prophylactic Antibiotic Regimens in Tumor Surgery), which is not on this map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): A Multi-Center International Randomized Controlled Trial Comparing Alternative Antibiotic Regimens in Patients Undergoing Tumor Resections With Endoprosthetic Replacements
Who cites it
29 citing papers in PubMed, 90 citations in OpenAlex.
- The Burden of Surgical Site Infections With Pathogens Presumably Resistant to Perioperative Prophylaxis in Orthopedic Tumor Surgery: Secondary Analysis of the Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) Trial.The Journal of infectious diseases · 2026Trial
- Shorter Versus Prolonged Systemic Perioperative Antibiotic Prophylaxis in Clean Orthopedic Surgery: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2026Review
- Is It Safe to Implant Prosthesis When Frozen Section Reports Positive During Joint Arthroplasty? A Retrospective Cohort Study.Orthopaedic surgery · 2026Article
- [Perioperative antibiotic prophylaxis-current clinical practise in total joint arthroplasty (TJA) in Germany and establishment of an standard operating procedure (SOP) for primary, revision, and tumor TJA].Orthopadie (Heidelberg, Germany) · 2026Article
- Multifunctional nanoplatforms deciphering immune resistance in bone tumors: cooperative delivery, immune reprogramming and microenvironment remodeling.Journal of nanobiotechnology · 2026Review
- Deep learning ensemble models for CT-based differentiation of malignant and benign sacral bone tumors: development and evaluation.Insights into imaging · 2026Article
- From suspected necrotizing fasciitis to diagnosed drug-induced fever: a diagnostic maze and reflections on anti-infection management in a case of postoperative fever after femoral fracture.Frontiers in medicine · 2026Article
- Machine learning prediction of early reoperation following lower extremity tumor resection and endoprosthetic reconstruction: A PARITY trial secondary analysis.Journal of orthopaedic surgery and research · 2025Article
- CORR Insights®: What Are the Complications, Reconstruction Survival, and Functional Outcomes of Modular Prosthesis and Allograft-prosthesis Composite for Proximal Femur Reconstruction in Children With Primary Bone Tumors?Clinical orthopaedics and related research · 2025Article
- CORR Insights®: Can Periprosthetic Joint Infection of Tumor Prostheses Be Controlled With Debridement, Antibiotics, and Implant Retention?Clinical orthopaedics and related research · 2025Article
- Endoprosthetic Reconstruction for Proximal Humerus Tumors.Current reviews in musculoskeletal medicine · 2025Review
- Rethinking antibiotic prophylaxis in orthopaedic oncology: insights from a cohort study of endoprosthetic infections.Journal of bone and joint infection · 2025Article
- Development of Machine Learning Models for Predicting the 1-Year Risk of Reoperation After Lower Limb Oncological Resection and Endoprosthetic Reconstruction Based on Data From the PARITY Trial.Journal of surgical oncology · 2024Article
- Prolonged prophylactic antibiotic use following megaprosthesis surgery may reduce periprosthetic infection.Journal of orthopaedics · 2024Article
- Postoperative challenges addressed through nursing care of patients receiving lower extremity tumor prosthesis.BMC nursing · 2024Article
- Comparison of Different Fusion Radiomics for Predicting Benign and Malignant Sacral Tumors: A Pilot Study.Journal of imaging informatics in medicine · 2024Article
- Preventing Surgical Site Infections in the Era of Escalating Antibiotic Resistance and Antibiotic Stewardship.JAMA surgery · 2024Review
- Surgical site infections after sarcoma resections in the peripelvic region: do we need perioperative antibiotic prophylaxis?Frontiers in oncology · 2024Article
- Risk Factors and Management of Prosthetic Joint Infections in Megaprostheses-A Review of the Literature.Antibiotics (Basel, Switzerland) · 2023Review
- Closed-incision negative-pressure wound therapy (ciNPWT) to minimize wound-related complications in lower limb reconstruction after bone tumor resection: preliminary proof-of-concept study.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2023Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
25 authors at 12 institutions in 6 countries.
Funding
Abstract
importanceThe use of perioperative, prophylactic, intravenous antibiotics is standard practice to reduce the risk of surgical site infection after oncologic resection and complex endoprosthetic reconstruction for lower extremity bone tumors. However, evidence guiding the duration of prophylactic treatment remains limited.
objectiveTo assess the effect of a 5-day regimen of postoperative, prophylactic, intravenous antibiotics compared with a 1-day regimen on the rate of surgical site infections within 1 year after surgery. DESIGN, SETTING, AND
participantsThis randomized clinical superiority trial was performed at 48 clinical sites in 12 countries from January 1, 2013, to October 29, 2019. The trial included patients with a primary bone tumor or a soft tissue sarcoma that had invaded the femur or tibia or oligometastatic bone disease of the femur or tibia with expected survival of at least 1 year who required surgical management by excision and endoprosthetic reconstruction. A total of 611 patients were enrolled, and 7 were excluded for ineligibility.
interventionsA 1- or 5-day regimen of postoperative prophylactic intravenous cephalosporin (cefazolin or cefuroxime) that began within 8 hours after skin closure and was administered every 8 hours thereafter. Those randomized to the 1-day regimen received identical saline doses every 8 hours for the remaining 4 days; patients, care providers, and outcomes assessors were blinded to treatment regimen. MAIN OUTCOMES AND MEASURES: The primary outcome in this superiority trial was a surgical site infection (superficial incisional, deep incisional, or organ space) classified according to the criteria established by the Centers for Disease Control and Prevention within 1 year after surgery. Secondary outcomes included antibiotic-related complications, unplanned additional operations, oncologic and functional outcomes, and mortality.
resultsOf the 604 patients included in the final analysis (mean [SD] age, 41.2 [21.9] years; 361 [59.8%] male; 114 [18.9%] Asian, 43 [7.1%] Black, 34 [5.6%] Hispanic, 15 [2.5%] Indigenous, 384 [63.8%] White, and 12 [2.0%] other), 293 were randomized to a 5-day regimen and 311 to a 1-day regimen. A surgical site infection occurred in 44 patients (15.0%) allocated to the 5-day regimen and in 52 patients (16.7%) allocated to the 1-day regimen (hazard ratio, 0.93; 95% CI, 0.62-1.40; P = .73). Antibiotic-related complications occurred in 15 patients (5.1%) in the 5-day regimen and in 5 patients (1.6%) allocated to the 1-day regimen (hazard ratio, 3.24; 95% CI, 1.17-8.98; P = .02). Other secondary outcomes did not differ significantly between treatment groups. CONCLUSIONS AND RELEVANCE: This randomized clinical trial did not confirm the superiority of a 5-day regimen of postoperative intravenous antibiotics over a 1-day regimen in preventing surgical site infections after surgery for lower extremity bone tumors that required an endoprosthesis. The 5-day regimen group had significantly more antibiotic-related complications.
trial registrationClinicalTrials.gov Identifier: NCT01479283.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.